Mesothelioma patients in clinical trial see improved survival rate

"Mesothelioma patients participating in a phase 3 clinical trial experienced improved survival after taking the drugs Ranirnase and Doxorubicin, according to a report presented earlier this month at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
Researchers in Germany conducted the clinical trial on patients with inoperable malignant mesothelioma, a form of cancer ..." (2009-6-15)
Read more...